🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🥳 Happy #DNADay! 🧬 What better way to celebrate than with cycleHCR: one of our newest tools, developed by the Liu Lab, that uses a novel DNA barcode system to track hundreds of RNA & protein molecules in single cells within thick biological samples ➡️ janelia.org/news/new-metho…

Huge thanks to all the presenters of this year's SBUR Breakout Sessions and to our fantastic moderators, Drs. Travis Jerde and Kristina Penniston! #AUA25

Read "MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-Grade Serous #OvarianCancer" from Kenneth P Nephew, Chair of the Molecular Targets for Overcoming Resistance #AACR25 Minisymposium: doi.org/10.1158/2767-9… #OpenAccess

The #SuLab Allen Su and #ShafiLab Ayesha Shafi, PhD are presenting well at #AACR25 and soaking up all the impactful science being highlighted! #nextgen #prostatecancer

🔬Not just mutations. 🧬Not just methylation. The new frontier in early cancer detection? The cfDNA fragmentome—size, shape, structure, and silence. nature International Society of Liquid Biopsy OncoAlert doi.org/10.1038/s41568…

Australian voters are unlike any others in the world. #australiavotes #ElectionDay #auspol

Meet our next featured trainee: Mingyu Liu, MS, from UMass Boston! Mingyu earned an SBUR Travel Award and was selected for a podium presentation—congrats! "We designed a workflow called Super-Enhancer Analysis for Lineages, and identified three... 1/3

A Gentle Introduction to Spatial Transcriptomic Analysis with 10X Visium Data biorxiv.org/content/10.110…

JUST IN/Big news for #bladdercancer: PDL1 inhibitor Durvalumab regimen demonstrated improvement in DFS for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial. News from AstraZeneca this morning! Bladder Cancer Advocacy Network Dana-Farber Lank Center for Genitourinary Oncology astrazeneca.com/media-centre/p…

Happening now - #ShafiLab Ayesha Shafi, PhD postdoc, Arwa, presents her work on circadian dysfunction mediating metabolic rewiring in prostate cancer Uniformed Services University Postdoctoral Research Symposium.

Former US President Biden spent much of his time advocating for cancer research. We all are familiar with his “moonshot” program. Today, his prostate cancer diagnosis reminds us how vulnerable we all are. We all wish him well as he faces this serious illness.

At Center for Prostate Disease Research we driving new ways to view #prostatecancer providing new understanding - new biomarkers - new therapeutics

What a fantastic talk by Beatriz and EllisLab_ at the Cedars-Sinai Single Cell and Spatial Omics Symposium! We’re proud to enable such exciting insights.

Meet Mostafa Nasr, an SBUR Travel Award Winner from the University of South Florida, who was also selected for podium presentation! "Induction of the transcription factor, PRDM16, in prostate cancer cells is critical for the initiation of an intrinsic dormancy program that... 1/2

If you work on cancer, DepMap is a great resource to mine depmap.org/portal/home/#/

Updated data from #PSMA monitoring study in #BCR #ProstateCancer ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

Congrats Ken!!! Well deserved

Love it!!! How many coffees was this 🤓

📢 #ASCO25 | Multimodal Artificial Intelligence (MMAI) Biomarker for ARPI Benefit Ph. II | M0 High-Risk Prostate Cancer: In STAMPEDE n=1,336, top-quartile MMAI patients derive a PCa-specific mortality benefit from adding abiraterone +/- enzalutamide (HR 0.42 vs 0.85); 5 year PCSM